DOSING AND
ADMINISTRATION

KEVZARA offers every-2-week dosing, is available in 2 doses and 2 devices, and can be kept at room temperature for up to 14 days.1,2

KEVZARA OFFERS CONSISTENT EVERY-2-WEEK DOSING1

The recommended starting dosage for KEVZARA is 200 mg once every 2 weeks, given as a subcutaneous injection.
  • No dose adjustments are recommended based on age, gender, race, or weight
  • KEVZARA can be used with or without MTX or other conventional DMARD(s)*
  • Reduce the dose to 150 mg q2w for the management of neutropenia, thrombocytopenia, and elevated liver enzymes
DOSE MODIFICATION FOR PATIENTS WHO NEED IT
  • KEVZARA initiation is not recommended in patients with an ANC <2000 per mm3, platelet count <150,000 per mm3, or ALT or AST >1.5 x ULN1
  • If a patient develops a serious infection, hold treatment with KEVZARA until the infection is controlled1
DOSAGE MODIFICATIONS1
LAB VALUE RECOMMENDATION
Low absolute neutrophil count (cells/mm3)
ANC >1000 Maintain current dosage of KEVZARA.
ANC 500-1000 Hold treatment with KEVZARA until ANC >1000. KEVZARA can then be resumed at 150 mg every 2 weeks and increased to 200 mg every 2 weeks as clinically appropriate.
ANC <500 Discontinue KEVZARA.
Low platelet count (cells/mm3)
50,000-100,000 Hold treatment with KEVZARA until platelets >100,000. KEVZARA can then be resumed at 150 mg every 2 weeks and increased to 200 mg every 2 weeks as clinically appropriate.
<50,000 If confirmed by repeat testing, discontinue KEVZARA.
Liver enzyme abnormalities
ALT >1 to ≤ 3 x ULN Consider dosage modification of concomitant DMARDs as clinically appropriate..
ALT >3 to ≤ 5 x ULN Hold treatment with KEVZARA until ALT <3 x ULN. KEVZARA can then be resumed at 150 mg every 2 weeks and increased to 200 mg every 2 weeks as clinically appropriate.
ALT >5 x ULN Discontinue KEVZARA.
  • * Dosing of MTX and other conventional DMARD(s) may vary.

MTX=methotrexate; DMARDs=disease-modifying antirheumatic drugs; ANC=absolute neutrophil count; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal.

KEVZARA IS AVAILABLE IN A PRE-FILLED SYRINGE OR A PRE-FILLED, BUTTON-FREE PEN2

The pre-filled, button-free KEVZARA pen

KEVZARA® (sarilumab) auto-injector pen for rheumatoid arthritis treatment

A real-world usability study in patients with RA demonstrated 2*†:

OF PATIENTS WERE SATISFIED TO VERY SATISFIED
WITH THE KEVZARA PEN

OF PATIENTS WERE VERY TO EXTREMELY CONFIDENT THAT THEY WOULD BE ABLE TO GIVE THEMSELVES INJECTIONS WITH THE KEVZARA PEN AFTER THIS STUDY

OF PATIENTS FOUND THE KEVZARA
PEN EASY TO VERY EASY TO USE

  • *EASY Study Description: A 12-week, global, phase 3, randomized, multicenter, open-label study of 217 adult patients with active moderate-to-severe rheumatoid arthritis designed to assess usability of the KEVZARA pen, of which 108 patients were randomized to the KEVZARA pen. The primary endpoint was defined as number of validated product technical failures (product technical complaint with validated technical cause). One of the secondary objectives was to assess satisfaction with the KEVZARA pen. A total of 600 successful injections were reported during the 12-week study period.2
  • 55% of patients had past experience with self-injection. All patients were trained on the use of the KEVZARA pen prior to first injection.2

KEVZARA is available by prescription only.

The KEVZARA packaging, pre-filled pen and pre-filled syringe received an Arthritis Foundation Ease of Use Commendation after independent testing by experts and evaluation by people with arthritis. Products receiving the Commendation make certain aspects of life easier for people with RA.3,4
KEVZARA comes in a pre-filled syringe or a pre-filled, button-free pen.
Both should be refrigerated, but either can be kept at room temperature
(≤77°F) for up to 14 days,
if needed.1,2

RA=rhematoid arthritis.

References:

  1. KEVZARA [prescribing information]. Bridgewater, NJ: Sanofi/Regeneron Pharmaceuticals, Inc.
  2. Kivitz A, Baret-Cormel L, van Hoogstraten H, et al. Usability and patient preference phase 3 study of the sarilumab pen in patients with active moderate-to-severe rheumatoid arthritis. Rheumatol Ther. 2018;5(1):231-242.
  3. Ease of use products. Arthritis Foundation website. http://www. arthritis.org/living-with-arthritis/tools-resources/ease-of-use. Accessed September 4, 2019.
  4. Data on file, Sanofi/Regeneron. Regeneron Sarilumab Evaluation Report of Consumer Product Accessibility for Users with Arthritis. February 2015.